Abstract:BACKGROUND:To determine the potential value of serum tumor markers in predicting pCR (pathological complete response) during neoadjuvant chemotherapy. MATERIALS AND METHODS:We retrospectively monitored the pro-, mid-, and post- neoadjuvant treatment serum tumor marker concentrations in patients with locally advanced breast cancer (stage II-III) who accepted pre-surgical chemotherapy or chemotherapy in combination with targeted therapy at Fudan University Shanghai Cancer Center between September 2011 and January 2014 and investigated the association of serum tumor marker levels with therapeutic effect. Core needle biopsy samples were assessed using immunohistochemistry (IHC) prior to neoadjuvant treatment to determine hormone receptor, human epidermal growth factor receptor 2(HER2), and proliferation index Ki67 values. In our study, therapeutic response was evaluated by pCR, defined as the disappearance of all invasive cancer cells from excised tissue (including primary lesion and axillary lymph nodes) after completion of chemotherapy. Analysis of variance of repeated measures and receiver operating characteristic (ROC) curves were employed for statistical analysis of the data. RESULTS:A total of 348 patients were recruited in our study after excluding patients with incomplete clinical information. Of these, 106 patients were observed to have acquired pCR status after treatment completion, accounting for approximately 30.5% of study individuals. In addition, 147patients were determined to be Her-2 positive, among whom the pCR rate was 45.6% (69 patients). General linear model analysis (repeated measures analysis of variance) showed that the concentration of cancer antigen (CA) 15-3 increased after neoadjuvant chemotherapy in both pCR and non-pCR groups, and that there were significant differences between the two groups (P=0.008). The areas under the ROC curves (AUCs) of pre-, mid-, and post-treatment CA15-3 concentrations demonstrated low-level predictive value (AUC=0.594, 0.644, 0.621, respectively). No significant differences in carcinoembryonic antigen (CEA) or CA12-5 serum levels were observed between the pCR and non-pCR groups (P=0.196 and 0.693, respectively). No efficient AUC of CEA or CA12-5 concentrations were observed to predict patient response toward neoadjuvant treatment (both less than 0.7), nor were differences between the two groups observed at different time points. We then analyzed the Her-2 positive subset of our cohort. Significant differences in CEA concentrations were identified between the pCR and non-pCR groups (P=0.039), but not in CA15-3 or CA12-5 levels (p=0.092 and 0.89, respectively). None of the ROC curves showed underlying prognostic value, as the AUCs of these three markers were less than 0.7. The ROC-AUCs for the CA12-5 concentrations of inter-and post-neoadjuvant chemotherapy in the estrogen receptor negative HER2 positive subgroup were 0.735 and 0.767, respectively. However, the specificity and sensitivity values were at odds with each other which meant that improving either the sensitivity or specificity would impair the efficiency of the other. CONCLUSIONS:Serum tumor markers CA15-3, CA12-5, and CEA might have little clinical significance in predicting neoadjuvant treatment response in locally advanced breast cancer.

Serum Mirna-1 May Serve As a Promising Noninvasive Biomarker for Predicting Treatment Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Clinical Implications of Serum Mir-34A in Breast Cancer and Its Predictive Value for the Efficacy of Neoadjuvant Chemotherapy

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer

Identification of Mirna Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response

Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer

Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy.

Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy

Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.

Serum Microrna-155 As A Potential Biomarker To Track Disease In Breast Cancer

Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer

Serum Mir-27A is a Biomarker for the Prognosis of Non-Small Cell Lung Cancer Patients Receiving Chemotherapy

Graphene Oxide-Based Highly Sensitive Assay of Circulating MicroRNAs for Early Prediction of the Response to Neoadjuvant Chemotherapy in Breast Cancer

A Prognostic 10-Mirna Risk Score (10-Mirna RS) in Predicting Neoadjuvant Chemotherapy Sensitivity of Luminal Breast Cancer.

A Serum Microrna Signature As a Prognostic Factor for Patients with Advanced NSCLC and Its Association with Tissue Microrna Expression Profiles.

Abstract P4-07-13: High Microrna-621 Level Predicts a Better Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-Small Cell Lung Cancer

Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer

Serum Micrornas Related with Chemoradiotherapy Resistance in Advanced-Stage Cervical Squamous Cell Carcinoma

Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.

Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer

Identification of Serum Mir-1915-3p and Mir-455-3p As Biomarkers for Breast Cancer.